Evidence supporting the standardisation of extragenital gonorrhoea and chlamydia screenings for women.


Journal

Sexually transmitted infections
ISSN: 1472-3263
Titre abrégé: Sex Transm Infect
Pays: England
ID NLM: 9805554

Informations de publication

Date de publication:
12 2021
Historique:
received: 05 05 2020
revised: 26 10 2020
accepted: 28 11 2020
pubmed: 29 12 2020
medline: 1 12 2021
entrez: 28 12 2020
Statut: ppublish

Résumé

Current guidelines for women do not include extragenital screening for Demographic and clinical data of 4658 women attending a community health centre in Los Angeles, California, USA from 2015 to 2018 were examined. CT and NG were detected using nucleic acid amplification test (APTIMA Combo 2, Hologic Gen-Probe, San Diego, California). Demographic and behavioural factors were also examined to assess potentially missed NG/CT cases. Multivariable regression analyses were used to determine whether reported anal sex behaviour predicts NG/CT rectal infection. A total of 193 NG cases and 552 CT cases were identified; however, 53.9% of NG cases and 25.5% of CT cases were identified exclusively through extragenital screening. Of all positive cases of rectal CT, 87.0% did not report anal sex without a condom and 91.3% did not report any anal sex with their last sexual partner. Of all positive cases of rectal NG, 78.9% did not report anal sex without a condom and 76.3% did not report any anal sex with their last sexual partner. Anal sex with last partner was not predictive of NG/CT rectal infection. Relying solely on urogenital screening and reported behaviour misses NG/CT cases. Extragenital NG/CT screening should be conducted in all women regardless of reported anal sex behaviour.

Identifiants

pubmed: 33361465
pii: sextrans-2020-054577
doi: 10.1136/sextrans-2020-054577
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

601-606

Informations de copyright

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Jamieson Trevor Jann (JT)

Health Services, Los Angeles LGBT Center, Los Angeles, California, USA tjann@lalgbtcenter.org.

Nicole J Cunningham (NJ)

Health Services, Los Angeles LGBT Center, Los Angeles, California, USA.

Ryan D Assaf (RD)

Health Services, Los Angeles LGBT Center, Los Angeles, California, USA.
Department of Epidemiology, University of California Los Angeles Jonathan and Karin Fielding School of Public Health, Los Angeles, California, USA.

Robert K Bolan (RK)

Health Services, Los Angeles LGBT Center, Los Angeles, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH